Tag Archive for: Shionogi & Co

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Deal value includes upfront payment of US$100 million with F2G eligible for additional regulatory and commercial milestones of up to US$380 million, as well as double-digit royalties on net sales and share development costs Validation of Novo Holdings’ strategy to identify and invest in promising European biotech opportunities Novo Holdings A/S, a leading international life sciences […]